US20190276464A1 - Novel Pharmaceutical Intermediates and Methods for Preparing the Same - Google Patents

Novel Pharmaceutical Intermediates and Methods for Preparing the Same Download PDF

Info

Publication number
US20190276464A1
US20190276464A1 US16/424,563 US201916424563A US2019276464A1 US 20190276464 A1 US20190276464 A1 US 20190276464A1 US 201916424563 A US201916424563 A US 201916424563A US 2019276464 A1 US2019276464 A1 US 2019276464A1
Authority
US
United States
Prior art keywords
alkyl
approximately
alkenyl
group
carbon atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/424,563
Inventor
William Allen Boulanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US16/424,563 priority Critical patent/US20190276464A1/en
Publication of US20190276464A1 publication Critical patent/US20190276464A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Definitions

  • the present invention relates in general to novel pharmaceutical intermediates and, more particularly, to novel indole derived pharmaceutical intermediates and methods for preparing the same.
  • novel compounds of the present invention are preferably suitable for participation in direct or multi-step convergent syntheses with other compounds including, but not limited to, aldehyde derived pharmaceutical intermediates, etcetera.
  • reaction conditions are such that significant side reactions occur, thereby: (1) adversely affecting the net yield; (2) materially increasing product cost; and (3) substantially increasing isolation and purification difficulties.
  • the above-identified problems are very difficult to solve because other types of classical protection of the nitrogen atom—such as carboxybenzyl groups or amides can prevent a desired reaction sequence altogether.
  • R 1 -R 4 , R 6 -R 8 , and R 10 -R 14 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 5 is selected from the group consisting of an alkyl (e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etcetera), allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 9 is selected from the group consisting of H; OH; and an alcohol, ether,
  • the pharmaceutical intermediate comprises the structure of formula II:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 2 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and
  • R 3 is selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate comprises the structure of formula III:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate comprises the structure of formula IV:
  • R 1 -R 3 are each independently selected from the group consisting of H, CH 3 , and C 6 H 5 .
  • exemplary examples of pharmaceutical intermediates may comprise
  • the present invention is also directed to a pharmaceutical intermediate which comprises the structure of formula V:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 2 -R 4 and R 6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate comprises the structure of formula VI:
  • R 1 -R 3 are each independently selected from the group consisting of H, CH 3 , and C 6 H 5 ;
  • R 4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • exemplary examples of pharmaceutical intermediates may comprise the structures of formulae VII and/or VIII, namely:
  • the present invention is further directed to a pharmaceutical intermediate which comprises the structure of formula IX:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 2 -R 4 and R 6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and
  • R 5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate comprises the structure of formula X:
  • R 1 -R 3 are each independently selected from the group consisting of H, CH 3 , and C 6 H 5 ;
  • R 4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • exemplary examples of pharmaceutical intermediates may comprise the structures of formulae XI and/or XII, namely:
  • novel indole derived pharmaceutical intermediates have been discovered which are surprisingly effective and efficient in direct or multi-step convergent syntheses with other compounds including, but not limited to, aldehyde derived pharmaceutical intermediates, etcetera.
  • the indole derived pharmaceutical intermediates preferably include an indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, (e.g., formulae I-IV), an optionally carboxylated azonane moiety, (e.g., formulae IX-XII) or an additional optionally carboxylated indole moiety (e.g., formulae V-VIII) moiety, having an alkyl (e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etcetera), allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from the nitrogen atom of the same.
  • an alkyl e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etc
  • a pharmaceutical intermediate which comprises, consists, and/or consists essentially of the structure of formula I:
  • R 1 -R 4 , R 6 -R 8 , and R 10 -R 14 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 5 is selected from the group consisting of an alkyl (e.g., methyl, ethyl, t-butyl), allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 9 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or
  • the pharmaceutical intermediate of this embodiment may comprise consist, and/or consist essentially of the structure of formula II:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 2 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and
  • R 3 is selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate of this embodiment may comprise consist, and/or consist essentially of the structure of formula III:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate of this embodiment may comprise consist, and/or consist essentially of the structure of formula IV:
  • R 1 -R 3 are each independently selected from the group consisting of H, CH 3 , and C 6 H 5 .
  • Specific examples of indole derived pharmaceutical intermediates include, but are not limited to,
  • a pharmaceutical intermediate which comprises, consists, and/or consists essentially of the structure of formula V:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 2 -R 4 and R 6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and
  • R 5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate of this embodiment may comprise, consist, and/or consist essentially of the structure of formula VI:
  • R 1 -R 3 are each independently selected from the group consisting of H, CH 3 , and C 6 H 5 ;
  • R 4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • a pharmaceutical intermediate which comprises, consists, and/or consists essentially of the structure of formula IX:
  • R 1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
  • R 2 -R 4 and R 6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and
  • R 5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • the pharmaceutical intermediate of this embodiment may comprise, consist, and/or consist essentially of the structure of formula X:
  • R 1 -R 3 are each independently selected from the group consisting of H, CH 3 , and C 6 H 5 ;
  • R 4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • the reaction mixture turned from dark grey to light green over 30 hours, at which time the mixture was washed into a separatory funnel with diethyl ether (50 mL), hexanes (50 mL), and water (50 mL). The mixture was partitioned and the aqueous layer was set aside. The organics were washed with water (50 mL) then NaCl brine (50 mL). The combined aqueous washings were extracted with 100 ml EtOAc/Hexanes (1:1) and the combined organics were dried over sodium sulfate then concentrated under reduced pressure.
  • a mechanically stirred 3 L 3-neck round-bottomed flask was fitted with a Dean-Stark reflux apparatus, an N 2 bubbler, and heating mantle.
  • To the flask was charged the indole from Example I (104.9 g, 369 mmol), 4-(1,3-dioxolan-2-yl)-6-methoxyhexanal (5, n 2, R ⁇ OMe) (89.53 g, 443 mmol), and toluene (2.4 L).
  • the Dean-Stark trap was charged with 3 ⁇ molecular sieves.
  • the apparatus was flushed with nitrogen, and the mixture azeotropically refluxed for 12 hours.
  • reaction mixture was transferred to a separatory funnel and organic layer separated, then washed sequentially with water (80 mL) and NaCl brine (80 mL), dried over sodium sulfate, and concentrated.
  • NMR suggested the presence of unreacted starting material and the crude mixture was filtered through a 40 g silica gel plug with an EtOAc/Hexanes eluent.
  • the desired indole was isolated as a mixture of ⁇ and ⁇ ester diastereomers (22 g contaminated with staring material ⁇ , ⁇ unsaturated ester and aldehyde condensation partner, 2:1, ⁇ : ⁇ product mixture).
  • TLC EtOAc/Hexanes, 1:1
  • R f 0.7.
  • R, and R 1 -R 3 are each independently selected from the group consisting of H, an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • allyl moieties as protecting groups
  • other protecting groups are likewise contemplated for use in accordance with the present invention including, but not limited to, alkyl groups (e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etcetera) containing approximately 1 to approximately 25 carbon atom(s).
  • alkyl groups e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etcetera
  • chloroformates e.g., methyl chloroformate
  • both neopentyl and adamantyl alkyl groups are void of beta hydrogen configurations, and, as such, can preclude certain degradation pathways known at beta positions.
  • any reference to compounds disclosed herein includes pharmaceutically acceptable salts and/or solvates of the same.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A pharmaceutical intermediate including a first indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, an optionally carboxylated azonane moiety, or a second, optionally carboxylated indole moiety, having an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from a nitrogen atom of the same.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 14/228,326, filed Mar. 28, 2014, entitled “Novel Pharmaceutical Intermediates and Methods for Preparing the Same” which is a divisional of U.S. application Ser. No. 13/346,815, filed Jan. 10, 2012, entitled “Novel Pharmaceutical Intermediates and Methods for Preparing the Same” which are hereby incorporated herein by reference in their entirety, including all references cited therein.
    • BACKGROUND OF THE INVENTION 1. Field of the Invention
  • The present invention relates in general to novel pharmaceutical intermediates and, more particularly, to novel indole derived pharmaceutical intermediates and methods for preparing the same. The novel compounds of the present invention are preferably suitable for participation in direct or multi-step convergent syntheses with other compounds including, but not limited to, aldehyde derived pharmaceutical intermediates, etcetera.
    • 2. Background Art
  • The commercial development of novel pharmaceutical compounds is, often times, replete with arduous problems relative to transitioning from research and development scale to plant scale synthesis. A plurality of complex issues, including reagent cost, reaction yield, reaction time, competitive side reactions, product isolation and/or purification, disposal of toxic waste and/or byproducts remain largely problematic for the scale-up of most pharmaceutical endeavors.
  • Problems associated with preparing novel pharmaceutical compounds can become exponentially difficult when, for example, intermediates comprise delicate compounds where one or more atoms, functional groups, and/or moieties need to be associated with a protecting group during one or more steps of a synthesis. For example, hexahydroazepinoindole-carboxylate intermediates comprise a nitrogen atom on the heptacyclic moiety which is commonly protected with a benzyl group during multi-step synthesis. However, obtaining a final product normally necessitates removing the benzyl group which is a great liability—especially at commercial scale. Notably, copious quantities of expensive catalyst (e.g., palladium) must be used to remove the benzyl group. To make matters more complex, reaction conditions are such that significant side reactions occur, thereby: (1) adversely affecting the net yield; (2) materially increasing product cost; and (3) substantially increasing isolation and purification difficulties. Notably, the above-identified problems are very difficult to solve because other types of classical protection of the nitrogen atom—such as carboxybenzyl groups or amides can prevent a desired reaction sequence altogether.
  • While indole derived pharmaceutical intermediates have been the subject of recent study, to the best of Applicant's knowledge, no such intermediates have been identified today that facilitate practical transition from research and development scale to commercial, plant scale synthesis.
  • It is therefore an object of the present invention to provide novel indole derived pharmaceutical intermediates and their syntheses which will partially and/or fully remedy the above-identified issues associated with the commercialized development of pharmaceuticals.
  • These and other objects of the present invention will become apparent in light of the present specification, claims, chemical structures, chemical formulae, and drawings.
    • SUMMARY OF THE INVENTION
  • In one embodiment the present invention is directed to a pharmaceutical intermediate which comprises the structure of formula I:
  • Figure US20190276464A1-20190912-C00001
  • wherein: R1-R4, R6-R8, and R10-R14 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R5 is selected from the group consisting of an alkyl (e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etcetera), allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R9 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and X1-X2 are each independently selected from the group consisting of N, O, and S.
  • In a preferred embodiment of the present invention, the pharmaceutical intermediate comprises the structure of formula II:
  • Figure US20190276464A1-20190912-C00002
  • wherein: R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R2 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and R3 is selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • In another preferred embodiment of the present invention, the pharmaceutical intermediate comprises the structure of formula III:
  • Figure US20190276464A1-20190912-C00003
  • wherein R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • In yet another preferred embodiment of the present invention, the pharmaceutical intermediate comprises the structure of formula IV:
  • Figure US20190276464A1-20190912-C00004
  • wherein R1-R3 are each independently selected from the group consisting of H, CH3, and C6H5.
  • In this embodiment of the present invention, exemplary examples of pharmaceutical intermediates may comprise
    • methyl 3-allyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate,
    • methyl 3-cinnamyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate,
    • methyl 3-(2-phenylallyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate,
    • methyl 3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate, and combinations thereof.
  • The present invention is also directed to a pharmaceutical intermediate which comprises the structure of formula V:
  • Figure US20190276464A1-20190912-C00005
  • wherein: R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R2-R4 and R6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and R5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • In a preferred embodiment of the present invention, the pharmaceutical intermediate comprises the structure of formula VI:
  • Figure US20190276464A1-20190912-C00006
  • wherein: R1-R3 are each independently selected from the group consisting of H, CH3, and C6H5; R4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • In this embodiment of the present invention, exemplary examples of pharmaceutical intermediates may comprise the structures of formulae VII and/or VIII, namely:
  • Figure US20190276464A1-20190912-C00007
  • The present invention is further directed to a pharmaceutical intermediate which comprises the structure of formula IX:
  • Figure US20190276464A1-20190912-C00008
  • wherein: R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R2-R4 and R6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and R5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • In a preferred embodiment of the present invention, the pharmaceutical intermediate comprises the structure of formula X:
  • Figure US20190276464A1-20190912-C00009
  • wherein: R1-R3 are each independently selected from the group consisting of H, CH3, and C6H5; R4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • In this embodiment of the present invention, exemplary examples of pharmaceutical intermediates may comprise the structures of formulae XI and/or XII, namely:
  • Figure US20190276464A1-20190912-C00010
    • DETAILED DESCRIPTION OF THE INVENTION
  • While this invention is susceptible of embodiment in many different forms, there is shown in the structural formulas and described herein in detail several specific embodiments with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the invention to the embodiments illustrated. It will be understood that the structural formulas disclosed herein are intended to comprise all stereochemical configurations regardless of graphical representations.
  • In accordance with the present invention, and as is shown herein below, novel indole derived pharmaceutical intermediates have been discovered which are surprisingly effective and efficient in direct or multi-step convergent syntheses with other compounds including, but not limited to, aldehyde derived pharmaceutical intermediates, etcetera. By way of broad characterization, the indole derived pharmaceutical intermediates preferably include an indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, (e.g., formulae I-IV), an optionally carboxylated azonane moiety, (e.g., formulae IX-XII) or an additional optionally carboxylated indole moiety (e.g., formulae V-VIII) moiety, having an alkyl (e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etcetera), allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from the nitrogen atom of the same.
  • In a first embodiment of the present invention, a pharmaceutical intermediate is disclosed which comprises, consists, and/or consists essentially of the structure of formula I:
  • Figure US20190276464A1-20190912-C00011
  • wherein: R1-R4, R6-R8, and R10-R14 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R5 is selected from the group consisting of an alkyl (e.g., methyl, ethyl, t-butyl), allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R9 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and X1-X2 are each independently selected from the group consisting of N, O, and S. It will be understood that for the purpose of avoiding prolix, additional suitable examples for a plurality of R groups, including R9 are disclosed in U.S. Pat. No. 6,211,360—which is hereby incorporated herein by reference in its entirety—including all references referred to and/or cited therein.
  • More preferably, the pharmaceutical intermediate of this embodiment may comprise consist, and/or consist essentially of the structure of formula II:
  • Figure US20190276464A1-20190912-C00012
  • wherein: R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R2 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and R3 is selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • Yet more preferably, the pharmaceutical intermediate of this embodiment may comprise consist, and/or consist essentially of the structure of formula III:
  • Figure US20190276464A1-20190912-C00013
  • wherein R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
  • Additionally, the pharmaceutical intermediate of this embodiment may comprise consist, and/or consist essentially of the structure of formula IV:
  • Figure US20190276464A1-20190912-C00014
  • wherein: R1-R3 are each independently selected from the group consisting of H, CH3, and C6H5. Specific examples of indole derived pharmaceutical intermediates include, but are not limited to,
    • methyl 3-allyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate,
    • methyl 3-cinnamyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate,
    • methyl 3-(2-phenylallyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate,
    • methyl 3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate, and combinations thereof.
  • In a second embodiment of the present invention, a pharmaceutical intermediate is disclosed which comprises, consists, and/or consists essentially of the structure of formula V:
  • Figure US20190276464A1-20190912-C00015
  • wherein: R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R2-R4 and R6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and R5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • More preferably, the pharmaceutical intermediate of this embodiment may comprise, consist, and/or consist essentially of the structure of formula VI:
  • Figure US20190276464A1-20190912-C00016
  • wherein: R1-R3 are each independently selected from the group consisting of H, CH3, and C6H5; R4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • Specific examples of this embodiment include, but are not limited to, the structures of formulae VII and/or VIII, namely:
  • Figure US20190276464A1-20190912-C00017
  • In a third embodiment of the present invention, a pharmaceutical intermediate is disclosed which comprises, consists, and/or consists essentially of the structure of formula IX:
  • Figure US20190276464A1-20190912-C00018
  • wherein: R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); R2-R4 and R6 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and R5 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s).
  • More preferably, the pharmaceutical intermediate of this embodiment may comprise, consist, and/or consist essentially of the structure of formula X:
  • Figure US20190276464A1-20190912-C00019
  • wherein: R1-R3 are each independently selected from the group consisting of H, CH3, and C6H5; R4 is selected from the group consisting of an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • Specific examples of this embodiment include, but are not limited to, the structures of formulae XI and/or XII, namely:
  • Figure US20190276464A1-20190912-C00020
  • The invention is further described by the following examples.
  • It will be understood that, unless otherwise specified, the chemical reagents provided herein below, or their precursors, are available from common commercial chemical vendors, such as Sigma-Aldrich Chemical Co., of St. Louis, Mo.
    • EXAMPLE I Synthesis of methyl 3-allyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate
  • Figure US20190276464A1-20190912-C00021
  • A 72 L three-necked mechanically stirred round bottomed flask was set up with a reflux condenser. To the flask was charged dry tetrahydrofuran (10 L), and methyl 1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate (800 g, 3.27 mol). The mixture was stirred, and tetrabutylammonium bromide (21.1 g, 0.06 mol), anhydrous potassium carbonate (1.13 kg, 8.8 mol), and allyl bromide (29.7 mL, 396 g, 3.27 mol) were added sequentially in one lot each. After addition, the mixture was stirred at about 20° C. for 2.5 days. The mixture was diluted with (10 L) hexanes, filtered, and transferred to a separatory funnel. The solution was washed with water (2 L), saturated sodium chloride (1 L), dried over sodium sulfate, filtered, then concentrated to a dark green-brown oil (770 g), methyl 3-allyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate, suitably clean to be used in the next synthetic step. Yield=83%. TLC (EtOH/CH2Cl2, 1:9): Rf=0.7; 1H NMR (400 MHz, CDCl3): δ 2.79-2.86 (m, 1H), 2.90-3.09 (m, 4H), 3.28-3.43 (m, 3H), 3.78 (s, 3H), 4.02 (dd, J=1.6, 6.8 Hz, 1H), 5.23 (d, J=10.4 Hz, 1H), 5.27 (dd, J=1.4, 17 Hz, 1H), 5.90-6.00 (m, 1H), 7.11-7.19 (m, 2H), 7.29 (d, J=7.6 Hz, 1H), 7.53 (d, J=7.2 Hz, 1H), 8.40 (bs, 1H); 13C NMR (100 MHz, CDCl3): δ 24.1, 45.4, 52.2, 55.7, 56.9, 61.4, 110.7, 113.8, 117.5, 118.0, 119.2, 121.4, 128.4, 132.1, 134.7, 135.7, 172.5; melting point: 105-108° C. (uncorrected).
    • EXAMPLE II Synthesis of methyl 3-cinnamyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate
  • Figure US20190276464A1-20190912-C00022
  • A 10 mL vial was charged with azepine (500 mg, 2.05 mmol) and tetrahydrofuran (4.0 mL). Potassium carbonate (565 mg, 4.09 mmol) was added at room temperature in a single portion to the stirred solution followed by addition of cinnamyl bromide (404 mg, 2.05 mmol) as a waxy solid. The reaction mixture was stirred 22 hours then washed into a separatory funnel with hexanes (10 mL), EtOAc (10 mL), and water (10 mL). The layers were partitioned and the organics were washed with water (10mL), NaCl brine (10 mL), dried over sodium sulfate, and concentrated to an oil. 1H NMR (400 MHz, CDCl3): δ 2.85-3.09 (m, 4H), 3.15 (dd, J=4.0, 12.0 Hz, 1H), 3.37-3.54 (m, 3H), 4.10 (dd, J=4.0, 8.0 Hz, 1H), 6.27-6.40 (m, 1H), 6.58 (d, J=16.0 Hz, 1H), 7.06-7.18 (m, 2H), 7.22-7.27 (m, 1H), 7.28-7.44 (m, 5H), 7.50 (d, J=8.0 Hz, 1H), 8.39 (s, 1H).
    • EXAMPLE III Synthesis of methyl 3-(2-phenylallyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate
  • Figure US20190276464A1-20190912-C00023
  • A 250 mL round bottom flask was charged with azepine (13 g, 53.2 mmol), tetrahydrofuran (100 mL), and stirred as a dark grey suspension. Potassium carbonate (14.9 g, 107.8 mmol) was added in a single portion. A 5:1 mixture of α-bromomethylstyrene and α-methyl-β-bromostyrene (14.3 g, ca. 52.2 mmol α-bromomethylstyrene) was then added at room temperature in a rapid drop wise manner over 2 minutes. The reaction mixture turned from dark grey to light green over 30 hours, at which time the mixture was washed into a separatory funnel with diethyl ether (50 mL), hexanes (50 mL), and water (50 mL). The mixture was partitioned and the aqueous layer was set aside. The organics were washed with water (50 mL) then NaCl brine (50 mL). The combined aqueous washings were extracted with 100 ml EtOAc/Hexanes (1:1) and the combined organics were dried over sodium sulfate then concentrated under reduced pressure. Column chromatography (80 g silica gel, EtOAc/Hexanes eluent) provided the title compound as a yellow oil (18.13 g, 94.5%). TLC (EtOAc/Hexanes, 1:3): Rf=0.3; 1H NMR (400 MHz, CDCl3): δ 2.76-2.88 (m, 2H), 2.91-3.02 (m, 1H), 3.04-3.10 (m, 1H), 3.15 (dd, J=3.8, 12.0 Hz, 1H), 3.45 (dd, 8.0, 14.0 Hz, 1H), 3.62 (s, 3H), 3.69 (s, 2H), 4.06 (dd, J=2.2, 8.0 Hz, 1H), 5.31 (d, 1.0Hz, 1H), 5.54 (d, J=1.0 Hz, 1H), 7.06-7.17 (m, 2H), 7.26-7.37 (m, 4H), 7.49 (d, J=8.0 Hz, 1H), 7.54-7.58 (m, 2H), 8.31 (s, 1H); ESI-MS: m/z calculated for C23H25N2O2, 361.19, found 361.3 [M+H]+.
    • EXAMPLE IV Synthesis of methyl 3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole-5-carboxylate
  • Figure US20190276464A1-20190912-C00024
  • A 250 mL round bottom flask was charged with azepine (10.0 g, 40.93 mmol), tetrahydrofuran (80 mL), and potassium carbonate (11.31 g, 81.83 mmol) at room temperature; in that order. Prenyl bromide (4.73 mL, 40.93 mmol) was added in a rapid drop wise fashion over 2 minutes. The reaction mixture was stirred 21 hours, then additional prenyl bromide (1.0 mL, 8.65 mmol) was added and the reaction stirred an additional 3 hours (24 hours total reaction time) before washing into a separatory funnel with EtOAc (50 mL), hexanes (50 mL), and water (50 mL). The mixture was partitioned and the aqueous layer was set aside. The organics were washed with water (50 mL) then NaCl brine (50 mL). The combined aqueous washings were extracted with 100 ml EtOAc/Hexanes (1:1) and the combined organics were dried over sodium sulfate then concentrated under reduced pressure. Column chromatography provided the title compound as a yellow oil. TLC (EtOAc/Hexanes, 1:1): Rf=0.45; 1H NMR (400 MHz, CDCl3): δ 1.68 (s, 3H), 1.77 (s, 3H), 2.79-3.00 (m, 4H), 3.09 (dd, J=3.2, 12.0 Hz, 1H), 3.24-3.35 (m, 3H), 3.78 (s, 3H), 4.08 (dd, J=2.4, 8.0 Hz, 1H), 5.28-5.34 (m, 1H), 7.07-7.17 (m, 2H), 7.30 (d, J=8.0 Hz, 1H), 7.49 (d, J=8.0 Hz, 1H), 8.40 (s, 1H); ESI-MS: m/z calculated for C19H25N2O2, 313.19, found 313.3 [M+H]+.
    • EXAMPLE V Synthesis of methyl-(3aRS,4SR,11bRS)-3-allyl-2,3,3a,4,5,7-hexahydro-4-[2-ζ-1,3-dioxolan-2-yl)-4-methyloxy-1-butyl]-1H-pyrrolo[2,3-d]carbazole-6-carboxylate
  • Figure US20190276464A1-20190912-C00025
  • A mechanically stirred 3 L 3-neck round-bottomed flask was fitted with a Dean-Stark reflux apparatus, an N2 bubbler, and heating mantle. To the flask was charged the indole from Example I (104.9 g, 369 mmol), 4-(1,3-dioxolan-2-yl)-6-methoxyhexanal (5, n=2, R═OMe) (89.53 g, 443 mmol), and toluene (2.4 L). The Dean-Stark trap was charged with 3 Å molecular sieves. The apparatus was flushed with nitrogen, and the mixture azeotropically refluxed for 12 hours. The mixture was cooled to room temperature and poured into hexanes (4 L) while stirring. The mixture was filtered through Celite and concentrated to give 187.9 g 6a (R═OMe, R1═R2═R3═H, n=2) as an oil. The product was sufficiently clean to be taken directly to the next step. Yield=108%.
    • EXAMPLE VI Synthesis of methyl-(3aRS,4SR,11bRS)-3-(3,3-dimethylallyl)-2,3,3a,4,5,7-hexahydro-4-[2-ζ-1,3-dioxolan-2-yl)-4-methyloxy-1-butyl]-1H-pyrrolo[2,3-d]carbazole-6-carboxylate
  • Figure US20190276464A1-20190912-C00026
  • A 500 mL round bottom flask was charged with prenylazepine (12.8 g, 40.97 mmol), toluene (250 mL), and aldehyde (crude aldehyde of ˜50% purity; ca. 21.5 g, 41 mmol), and a condenser. The reaction mixture was heated to a gentle reflux and stirred 15 hours, at which time the solution was concentrated under reduced pressure and filtered through a column of silica gel (120 g) with and EtOAc/Hexane eluent. The title compound was isolated with substantial amounts of components of the crude aldehyde starting material as an oil (34.21 g). TLC (EtOAc/Hexanes, 1:1): Rf=0.4; ESI-MS: m/z calculated for C29H41N2O5, 497.30, found 497.3 [M+H]+.
  • N.B., The later column fractions provided material potentially sufficient for NMR analysis: 1H NMR (400 MHz, CDCl3): δ 0.68-1.44 (m, 5H), 1.61-1.73 (m, 3H), 1.74 (s, 3H), 1.78 (s, 3H), 1.96-2.10 (m, 2H), 2.39-2.48 (m, 1H), 2.52-2.76 (m, 2H), 2.82 (d, J=8.0 Hz, 1H), 3.04 (dd, J=6.0, 8.0 Hz, 1H), 3.13 (s, 1.5H), 3.16-3.36 (m, 5H), 3.43-3.54 (m, 1H), 3.58-3.89 (m, 7H), 4.64 (d, J=4.0 Hz, 0.5H), 4.70 (d, J=4.0 Hz, 0.5H), 5.39-5.48 (m, 1H), 6.81 (dd, J=2.0, 8.0 Hz, 1H), 6.83-6.91 (m, 1H), 7.10-7.19 (m, 2H), 8.93-9.05 (m, 1H).
    • EXAMPLE VII Synthesis of 3-allyl-1,2,3,4,5,6,7,8-octahydro-5β-[2-λ-(1,3-dioxolan-2-yl)-4-methyloxy-1-butyl]azonino[5,4-b]indole-7-carboxylate
  • Figure US20190276464A1-20190912-C00027
  • A 2 liter 3 neck round-bottomed flask was set up with a mechanical stirrer, temperature-controlled oil bath and reflux condenser. The compound obtained from Example V (R═OMe, R1═R2═R3═H, n=2) (172.91 g, 369 mmol) and glacial acetic acid (738 mL) were charged to the flask, and the mixture brought to 90° C. Sodium borohydride (41.88 g, 1.11 mol) was added in small portions at such a rate as to control the ensuing reaction. After the addition was complete, the reaction mixture was poured over ice and quenched with saturated ammonium hydroxide. (Alternately, approximately ⅔ of the glacial acetic acid may be removed under reduced pressure prior to pouring on ice and making basic with ammonium hydroxide. This significantly reduces the amount of ammonium hydroxide required.) The aqueous mixture was extracted with ether several times, the extracts dried over sodium sulfate, filtered and concentrated in vacuo to give 165.2 g of the titled compound as an oil. Yield=95%.
    • EXAMPLE VIII Synthesis of 3-(3,3-dimethylallyl)-1,2,3,4,5,6,7,8-octahydro-5β-[2-ζ-(1,3-dioxolan-2-yl)-4-methyloxy-1-butyl]azonino[5,4-b]indole-7-carboxylate
  • Figure US20190276464A1-20190912-C00028
  • A 1 L round bottom flask was charged with crude α,β unsaturated ester (33 g, <40 mmol), glacial acetic acid (250 mL), and heated to 80° C. in an oil bath. NaBH4 (7.6 g, 201 mmol) was added portion wise (100-500 mg portions) to the hot reaction mixture over 33 minutes. After stirring an additional 13 minutes, NaBH4 (3.8 g, 100.5 mmol) was added portion wise (100-500 mg portions) over 5 minutes. After stirring an additional 15 minutes, NaBH4 (3.8 g, 100.5 mmol) was added portion wise (100-500 mg portions) over 5 minutes. After stirring an additional 15 minutes, NaBH4 (3.8 g, 100.5 mmol) was added portion wise (100-500 mg portions) over 5 minutes. After stirring an additional 15 minutes, NaBH4 (3.8 g, 100.5 mmol) was added portion wise (100-500 mg portions) over 5 minutes. At this point 22.8 g NaBH4 had been added and TLC indicated no remaining starting material. The mixture was concentrated under reduced pressure to ⅓ the original volume and diluted with isopropyl acetate (250 mL) with vigorous stirring. The reaction flask was placed in a 0° C. ice bath and concentrated NH4OH (140 mL) was added at room temperature. The reaction mixture was transferred to a separatory funnel and organic layer separated, then washed sequentially with water (80 mL) and NaCl brine (80 mL), dried over sodium sulfate, and concentrated. NMR suggested the presence of unreacted starting material and the crude mixture was filtered through a 40 g silica gel plug with an EtOAc/Hexanes eluent. The desired indole was isolated as a mixture of α and β ester diastereomers (22 g contaminated with staring material α,β unsaturated ester and aldehyde condensation partner, 2:1, β:α product mixture). TLC (EtOAc/Hexanes, 1:1): Rf=0.7.
  • Without being bound to any one particular direct or multi-step convergent synthesis, provided below in an exemplary embodiment of a synthesis which utilizes novel indole derived pharmaceutical intermediates in accordance with the present invention, wherein: R, and R1-R3 are each independently selected from the group consisting of H, an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s); and n is an integer ranging from approximately 2 to approximately 5.
  • Figure US20190276464A1-20190912-C00029
    Figure US20190276464A1-20190912-C00030
  • It will be understood that while a plurality of the examples provided supra utilize allyl moieties as protecting groups, one of ordinary skill in the art having the present disclosure before them will appreciate that other protecting groups are likewise contemplated for use in accordance with the present invention including, but not limited to, alkyl groups (e.g., methyl, ethyl, t-butyl, neopentyl, adamantyl, etcetera) containing approximately 1 to approximately 25 carbon atom(s). By way example chloroformates (e.g., methyl chloroformate) are effective for removing such alkyl protecting groups. Notably, both neopentyl and adamantyl alkyl groups are void of beta hydrogen configurations, and, as such, can preclude certain degradation pathways known at beta positions.
  • It will be further understood that any reference to compounds disclosed herein includes pharmaceutically acceptable salts and/or solvates of the same.
  • The foregoing description merely explains and illustrates the invention and the invention is not limited thereto except insofar as the appended claims are so limited, as those skilled in the art who have the disclosure before them will be able to make modifications without departing from the scope of the invention.

Claims (5)

1. A pharmaceutical intermediate comprising the structure of formula I:
Figure US20190276464A1-20190912-C00031
wherein:
R1-R4, R6-R8, and R10-R14 are each independently selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
R5 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
R9 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and
X1-X2 are each independently selected from the group consisting of N, O, and S.
2. The pharmaceutical intermediate according to claim 1, comprising the structure of formula II:
Figure US20190276464A1-20190912-C00032
wherein:
R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s);
R2 is selected from the group consisting of H; OH; and an alcohol, ether, ester, amide, hydrazide, cyanide, and/or ketone group containing approximately 1 to approximately 25 carbon atom(s); and
R3 is selected from the group consisting of H; OH; and an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
3. The pharmaceutical intermediate according to claim 1, comprising the structure of formula III:
Figure US20190276464A1-20190912-C00033
wherein:
wherein R1 is selected from the group consisting of an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl group containing approximately 1 to approximately 25 carbon atom(s).
4. The pharmaceutical intermediate according to claim 1, comprising the structure of formula IV:
Figure US20190276464A1-20190912-C00034
wherein:
R1-R3 are each independently selected from the group consisting of H, CH3, and C6H5.
5-18. (canceled)
US16/424,563 2012-01-10 2019-05-29 Novel Pharmaceutical Intermediates and Methods for Preparing the Same Abandoned US20190276464A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/424,563 US20190276464A1 (en) 2012-01-10 2019-05-29 Novel Pharmaceutical Intermediates and Methods for Preparing the Same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/346,815 US20130178618A1 (en) 2012-01-10 2012-01-10 Novel pharmaceutical intermediates and methods for preparing the same
US14/228,326 US10906912B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same
US16/424,563 US20190276464A1 (en) 2012-01-10 2019-05-29 Novel Pharmaceutical Intermediates and Methods for Preparing the Same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/228,326 Continuation US10906912B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same

Publications (1)

Publication Number Publication Date
US20190276464A1 true US20190276464A1 (en) 2019-09-12

Family

ID=48744348

Family Applications (7)

Application Number Title Priority Date Filing Date
US13/346,815 Abandoned US20130178618A1 (en) 2012-01-10 2012-01-10 Novel pharmaceutical intermediates and methods for preparing the same
US14/228,316 Active 2032-06-07 US9399643B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same
US14/228,303 Active 2032-05-22 US9399642B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same
US14/228,326 Active US10906912B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same
US16/424,563 Abandoned US20190276464A1 (en) 2012-01-10 2019-05-29 Novel Pharmaceutical Intermediates and Methods for Preparing the Same
US17/136,103 Active 2033-03-10 US11827643B2 (en) 2012-01-10 2020-12-29 Pharmaceutical intermediates and methods for preparing the same
US18/521,224 Pending US20240140956A1 (en) 2012-01-10 2023-11-28 Novel Pharmaceutical Intermediates and Methods for Preparing the Same

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US13/346,815 Abandoned US20130178618A1 (en) 2012-01-10 2012-01-10 Novel pharmaceutical intermediates and methods for preparing the same
US14/228,316 Active 2032-06-07 US9399643B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same
US14/228,303 Active 2032-05-22 US9399642B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same
US14/228,326 Active US10906912B2 (en) 2012-01-10 2014-03-28 Pharmaceutical intermediates and methods for preparing the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/136,103 Active 2033-03-10 US11827643B2 (en) 2012-01-10 2020-12-29 Pharmaceutical intermediates and methods for preparing the same
US18/521,224 Pending US20240140956A1 (en) 2012-01-10 2023-11-28 Novel Pharmaceutical Intermediates and Methods for Preparing the Same

Country Status (1)

Country Link
US (7) US20130178618A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130178618A1 (en) 2012-01-10 2013-07-11 William Allen Boulanger Novel pharmaceutical intermediates and methods for preparing the same
SG11202109111VA (en) 2019-02-27 2021-09-29 Univ California Azepino-indoles and other heterocycles for treating brain disorders

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3525750A (en) 1966-05-31 1970-08-25 Geigy Chem Corp 1,2,3,4,5,6-hexahydro-azepino(4,5-b) indole derivatives
US3478051A (en) 1967-03-17 1969-11-11 Sandoz Ag Azecino- and azonino(5,4-b)indoles
US3681362A (en) 1968-06-29 1972-08-01 Shionogi & Co Process for the preparation of isoquinuclidine alkaloids
US4146643A (en) 1973-12-18 1979-03-27 Sandoz Ltd. Increasing vigilance or treating cerebral insufficiency with substituted vincamines
FR2296418B1 (en) 1974-12-30 1978-07-21 Anvar
US4122082A (en) 1977-11-07 1978-10-24 Eli Lilly And Company 4-Desacetoxy-4-oxovinblastine
US4283536A (en) 1977-12-29 1981-08-11 University Of Vermont Preparation of vincadifformine and related derivatives
US4154943A (en) 1977-12-29 1979-05-15 University Of Vermont Preparation of vincadifformine
US4267330A (en) 1978-08-24 1981-05-12 Omnium Chimique Societe Anonyme Process for the synthesis of vincadifformine and related derivatives
US4220774A (en) 1978-10-26 1980-09-02 Omnium Chimique Vincadifformine synthesis process
HU181746B (en) 1980-10-22 1983-11-28 Richter Gedeon Vegyeszet Process for preparing vinblastine and leurosidine derivatives
US4362739A (en) 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
US4428880A (en) 1981-05-04 1984-01-31 S.A. Omnichem Azepino[4,5-d]indole derivatives and preparation thereof
ATE57187T1 (en) 1983-03-30 1990-10-15 Lilly Industries Ltd VINCALEUKOBLASTIN DERIVATIVES.
US4499096A (en) 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
US4558053A (en) 1983-12-21 1985-12-10 Eli Lilly And Company Naphthalene-1,5-disulfonate salts of dimeric indole-dihydroindole alkaloids
US4897477A (en) 1985-03-12 1990-01-30 University Of Vermont & State Agricultural College Synthesis of vinblastine and vincristine type compounds
US4841045A (en) 1985-03-12 1989-06-20 University Of Vermont & State Agricultural College Synthesis of vinblastine and vincristine type compounds
HU193772B (en) 1985-06-12 1987-11-30 Richter Gedeon Vegyeszet Process for producing new nitro-bis-indole derivatives
US4587243A (en) 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
FR2623504B1 (en) 1987-11-25 1990-03-09 Adir NOVEL N- (VINBLASTINOYL-23) DERIVATIVES OF 1-AMINO METHYLPHOSPHONIC ACID, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5095109A (en) 1989-06-08 1992-03-10 University Of Vermont Novel alkaloids
US4935509A (en) 1989-06-08 1990-06-19 University Of Vermont Novel alkaloids
WO1991015124A1 (en) 1990-04-10 1991-10-17 The University Of Vermont Modulator agent and use thereof
US5152994A (en) 1990-05-31 1992-10-06 Lotsof Howard S Rapid method for interrupting or attenuating poly-drug dependency syndromes
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
ES2268686T3 (en) 1994-09-22 2007-03-16 Richard Alan Smith COMBINATION OF DEXTROMETORPHAN WITH QUINIDINE OR QUININE SULFATE TO TREAT DIFFERENT CURE DISORDERS.
WO1997005869A1 (en) 1995-08-08 1997-02-20 Albany Medical College Ibogamine congeners
US5965567A (en) 1997-07-15 1999-10-12 Albany Medical College Method for treating nicotine addiction
EP1140074A1 (en) * 1998-12-23 2001-10-10 NPS Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
EP1319004A2 (en) * 2000-09-20 2003-06-18 PHARMACIA &amp; UPJOHN COMPANY Substituted azepino[4,5-b]indole derivatives
US6780871B2 (en) 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
CA2712553C (en) 2008-01-28 2016-06-21 Albany Medical College Use of ibogamine congeners for treating obesity
US20100152200A1 (en) 2008-11-17 2010-06-17 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
US20130178618A1 (en) * 2012-01-10 2013-07-11 William Allen Boulanger Novel pharmaceutical intermediates and methods for preparing the same

Also Published As

Publication number Publication date
US20140213783A1 (en) 2014-07-31
US20210115056A1 (en) 2021-04-22
US20140213797A1 (en) 2014-07-31
US11827643B2 (en) 2023-11-28
US9399642B2 (en) 2016-07-26
US20240140956A1 (en) 2024-05-02
US20130178618A1 (en) 2013-07-11
US10906912B2 (en) 2021-02-02
US20140213782A1 (en) 2014-07-31
US9399643B2 (en) 2016-07-26

Similar Documents

Publication Publication Date Title
US20240140956A1 (en) Novel Pharmaceutical Intermediates and Methods for Preparing the Same
Kalita et al. Synthesis of novel pyrano [2, 3-b] quinolines from simple acetanilides via intramolecular 1, 3-dipolar cycloaddition
Yang et al. A facile synthesis of highly functionalized dihydrofurans based on 1, 4-diazabicyclo [2.2. 2] octane (DABCO) catalyzed reaction of halides with enones
Srivastava et al. An approach towards the total synthesis of (+)-epiquinamide and (+)-α-conhydrine from Garner aldehyde
Sá et al. Synthesis of allylic thiocyanates and novel 1, 3-thiazin-4-ones from 2-(bromomethyl) alkenoates and S-nucleophiles in aqueous medium
EP0011059B1 (en) Process for the preparation of (+,-) vincadifformine and other related pentacyclic derivatives
PL214129B1 (en) Method for combrestatin production
US7674614B2 (en) Method of optically resolving racemic alcohols with a bicyclooxaoctane or a bicycooxaoctene resolving reagents
Soengas et al. Synthesis of polyhydroxylated α-nitrocyclohexane carboxylic acids derived from d-glucose: a striking case of racemization
Chadda et al. Allylic Azide Rearrangement in Tandem with Intramolecular Huisgen Cycloaddition for Iminosugar and Glycomimetic Synthesis: Functionalized Piperidine, Pyrrolidine, and Pyrrolotriazoles from D-Mannose
US9145364B2 (en) Synthesis of psuedo indoxyl derivatives
Janecki et al. Stereocontrolled synthesis of 5-(1′-hydroxyalkyl)-3-methylidenetetrahydro-2-furanones
Kurteva et al. Spontaneous conversion of O-tosylates of 2-(piperazin-1-yl) ethanols into chlorides during classical tosylation procedure
Leyva et al. Photochemistry of 7-azide-1-ethyl-3-carboxylate-6, 8-difluoroquinolone: a novel reagent for photoaffinity labeling
FR2792635A1 (en) 2-Amino-cyclobutene-3,4-dione cyclohexane carboxamide derivatives are phosphodiesterase inhibitors useful for treating e.g. incontinence, dysmenorrhea, premature labor, sexual dysfunction, angina and asthma
FR2479831A1 (en) THIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP0165225B1 (en) Process for the preparation of 5-azaindole and intermediates
Egorov et al. Design and synthesis of novel polyheterofunctionalyzed cyclopentenones
KR100226622B1 (en) Novel synthetic intermediate of muscone and the preparation thereof
Muthusamy et al. PPh3-mediated reactions of diazoimides in water: a facile synthesis of fused triazine derivatives
FR2792634A1 (en) New 2-alkoxy cyclobutene-3,4-dione derivatives are phosphodiesterase-5 inhibitors, useful for treating e.g. incontinence, dysmenorrhea, premature labor, sexual dysfunction, angina and asthma
Tamura et al. The effect of fluoromethyl groups on the diastereoselectivity in the electrophilic alkylation
AU697447B2 (en) Propenone derivatives
Bonjoch et al. Stereoselective synthesis and conformational analysis of cis-5-(2-nitrophenyl)-2-azabicyclo [3.3. 0] octan-6-ones
Kumar et al. A chiron approach to (1R, 2R, 5S, 7S)-2-hydroxy-exo-brevicomin: a component of the volatiles produced by the male mountain pine beetle, Dendroctonus ponderosae

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION